Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VISP

This article was originally published in The Tan Sheet

Executive Summary

More than 2,600 subjects enrolled in NIH-sponsored Vitamin Intervention for Stroke Prevention Study, with recruitment expected to continue through 2001, to reach 3,600-patient target, according to an abstract presented at the 26th International Stroke Conference in Fort Lauderdale, Fla. Feb. 14-16. VISP is a double-blind, randomized, controlled trial with centers in U.S., Canada and Scotland; subjects receive either low or high doses of folic acid, vitamins B6 and B12. Primary outcome is recurrent cerebral infarction. Separately, enrollment will continue until 2003 for 8,000-patient VITATOPS study examining whether B vitamins reduce combined incidence of recurrent vascular events and vascular death in patients with recent stroke or TIA. Study encompasses centers in Australia, New Zealand, Italy, U.K

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS092244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel